Your cart is empty
Hepatitis C drugs not being accessed
Hundreds of thousands of Australians with hepatitis C are failing to access new curative drugs, despite the Government subsidising them at huge cost to the taxpayer.
The trend means the Government is at risk of missing its target to eradicate hepatitis C and of spending far more than necessary on the treatments.
Hepatitis Australia said fewer than half as many people were accessing the direct acting antivirals as they were immediately after they were first listed on the Pharmaceutical Benefits Scheme (PBS) in March 2016.
